C34.2: Malignant neoplasm of middle lobe, bronchus or lung

Risk adjustment

C34.2 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:

• HCC 20 Lung and Other Severe Cancers1.136 RAF

Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score. Look up the whole chart to see which of its HCCs the hierarchy would zero.

Medicare coverage

C34.2 is named in 83 Medicare coverage policies: 83 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.

• A52370Billing and Coding: Bevacizumab and biosimilars
• A52399Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars
• A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
• A52479Oral Anticancer Drugs - Policy Article